Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Dalvance: First QIDP Antibiotic Breaks New Regulatory Ground; Label Doesn’t

Jun 02 2014

• By Derrick Gingery

Related Content

Antibiotic Development Incentives Face Critical Test As NDA Reviews Begin

Jan 20 2014

Antibiotics Legislation Could Boost Confidence Of Sponsors And FDA Alike

Jan 20 2014

Senate Prevails On PDUFA Antibiotic Incentive As House Vote Nears

Jun 19 2012

Zyvox Phase IV Studies May Support Penicillin-Resistant Indications

Apr 24 2000

Dalvance Approval Is Durata’s GAIN: First Test Of FDA’s Antibiotics Incentives

May 23 2014

Antibiotic Resistance Gets Attention Of FDA, Congress

Jun 07 2013

CDC’s Antibiotic-Resistance Battle Plan Emphasizes Preserving Current Drugs

Sep 17 2013

FDA Worries About Off-Label Use, Stewardship With Limited-Population Approval Pathway

Feb 11 2013

Related Companies

Cubist Pharmaceuticals, Inc.

Trius Therapeutics, Inc.

Additional Topics

United States Approvals BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window